Mizuho maintains Neutral on Amgen, raises target to $303
Mizuho analyst Salim Syed maintained a Neutral rating on Amgen (NASDAQ: AMGN) and raised the price target to $303 from $295, reflecting a revised valuation outlook.
*this image is generated using AI for illustrative purposes only.
Mizuho analyst Salim Syed has maintained a Neutral rating on Amgen (NASDAQ: AMGN) and raised the price target to $303 from $295. The adjustment reflects a revised valuation outlook for the biotechnology company.
Rating and Price Target Details
The research note confirms the Neutral stance, indicating a neutral expectation for the stock's performance relative to the broader market. The increase in the price target suggests a modest improvement in the firm's fair value estimate.
| Metric | Value |
|---|---|
| Rating | Neutral |
| Previous Price Target | $295 |
| New Price Target | $303 |
What specific factors drove the revised valuation outlook for Amgen?
How might Amgen's pipeline developments influence future analyst ratings?
What competitive pressures could impact Amgen's market performance?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
